In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

Monoclonal antibodies (mAb) are a major component of cancer therapy. In this review, we
summarize the different therapeutic mAbs that have been successfully developed against …

Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor involved in
homeostatic regulation of normal cells and carcinogenesis of epithelial malignancies. With …

Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the
epidermal growth factor receptor (EGFR), and both are widely used in combination with …

Immunoglobulin (Ig) G1 antibodies stimulate antibody-dependent cell-mediated cytotoxicity
(ADCC). Cetuximab, an IgG1 isotype monoclonal antibody, is a standard-of-care treatment …

Highlights•NK cells are cytotoxic lymphocytes with potential for cancer immunotherapy.•NK-
cell numbers and function are regulated by surface receptors and cytokines.•Inhibitory and …

The major development of the past decade in the first-line treatment of recurrent and/or
metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the …

Highlights•CD8+ T cells and NK cells are both cytotoxic cells with engineering potential.•NK
cells are comparable to CD8+ T cells but far less understood.•Cancer immunotherapies …

A safe and controlled manipulation of endocytosis in vivo may have disruptive therapeutic
potential. Here, we demonstrate that the anti-emetic/anti-psychotic prochlorperazine can be …